CA AB941

California Health and Human Services Agency must convene a workgroup to study and recommend a framework for psychedelic-assisted therapy using psilocybin, ibogaine, and FDA-approved controlled substances like DMT or mescaline.

Workgroup must include experts in psychedelic therapy, law enforcement, indigenous representatives, veterans groups, university researchers, and individuals from states with established psychedelic frameworks.

Workgroup shall study safety, efficacy, long-term impacts, regulatory models, educational campaigns, risk minimization, and therapist qualifications for psychedelic-assisted therapy treating PTSD, depression, anxiety, and addiction.

Workgroup must submit findings and policy recommendations to the Legislature by January 1, 2026, with this provision repealing January 1, 2027.

Upon Legislature enactment of a psychedelic-assisted therapy framework, use of hallucinogenic or psychedelic substances for lawful medical treatment in clinical settings shall be permitted, with transfer of such substances without financial gain in therapeutic contexts to be decriminalized.